PATENT ATTORNEY DOCKET NO. 06132/011001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pierre Michetti et al.

Art Unit: 1806

Serial No.: 08/200,346

Examiner:

: February 23, 1994

Filed Title

: UREASE-BASED VACCINE AND TREATMENT FOR HELICOBACTER

INFECTION

Commissioner of Patents and Trademarks Washington, DC 20231

## REVOCATION AND NEW POWER OF ATTORNEY

Under 37 CFR §3.73(b) OraVax, Inc., a corporation, certifies that it is the assignee of 100% of the right, title and interest in the patent application identified above by virtue of an assignment from the inventors of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 6993, Frame 0600 on April 25, 1994.

The undersigned, whose title is supplied below, is empowered to act on behalf of the assignee.

The undersigned, acting on behalf of the assignee, hereby revokes all powers of attorney previously granted in the application and appoints:

> Paul T. Clark, Reg. No. 30,162 Fish & Richardson P.C. 225 Franklin Street Boston, Massachusetts 02110-2804

with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.

All correspondence regarding the application should be sent to Paul T. Clark, Esq. at Fish & Richardson P.C., 225 Franklin Street, Boston, Massachusetts 02110-2804.

> Date of Deposit October 24 1995 I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

If there are any charges not covered, or any credits, please apply them to Deposit Account No. 06-1050.

Respectfully submitted,

Lance Gordon, Ph.D. President and Chief Executive Officer

OraVax, Inc.

Respectfully submitted,

Paul T. Clark Reg. No. 30,162

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804

Telephone: 617/542-5070 Facsimile: 617/542-8906

149135.B11